CALIFORNIA STD TREATMENT GUIDELINES TABLE FOR ADULTS & ADOLESCENTS 2007

These guidelines for the treatment of patients with STDs reflect the 2006 CDC STD Treatment Guidelines and the Region IX Infertility Clinical Guidelines. The focus is primarily on STDs encountered in office practice. These guidelines are intended as a source of clinical guidance; they are not a comprehensive list of all effective regimens and are not intended to substitute for use of the full 2006 STD treatment guidelines document. Call the local health department to report STD infections; to request assistance with confidential notification of sexual partners of patients with syphilis, gonorrhea, chlamydia or HIV infection; or to obtain additional information on the medical management of STD patients. The California STD/HIV Prevention Training Center is an additional resource for training and consultation in the area of STD clinical management and prevention (510-625-6000) or www.std.ca.gov.

### CHLAMYDIA

| Uncomplicated Genital/Rectal/Pharyngeal Infections | Ceftriaxone 1 or Doxycycline 2 | 1 g po 100 mg po bid x 7 d | Erythromycin base 500 mg po qid x 7 d or Erythromycin ethylsuccinate 800 mg po qid x 7 d or Levofloxacin 500 mg po qid x 7 d |
| Pregnant Women | Azithromycin or Amoxicillin | 1 g po 500 mg po tid x 7 d | Erythromycin base 500 mg po qid x 7 d or Erythromycin ethylsuccinate 800 mg po qid x 7 d or Erythromycin ethylsuccinate 400 mg po qid x 14 d |

### GONORRHEA

Ceftriaxone is the preferred treatment for adult and adolescent patients with uncomplicated gonorrhea infections. Fluoroquinolones are no longer recommended for treatment of gonococcal infections in California because of high levels of resistance to this class of drugs. Routine use of azithromycin to treat gonorrhea is not recommended because of mounting concern about emerging resistance. Complete guidelines for the treatment of gonorrhea in California are available at www.std.ca.gov.

| Uncomplicated Genital/Rectal Infections | Ceftriaxone or Cefixime plus Metronidazole if BV is present | 125 mg IM 400 mg po | Cefpodoxime 400 mg po or Spectinomycin 2 IM or Azithromycin 2 g po in a single dose |
| Pharyngeal Infections | Ceftriaxone or Cefixime plus Metronidazole if BV is present | 125 mg IM | Azithromycin 2 g po in a single dose |
| Pregnant Women | Ceftriaxone or Cefixime plus Metronidazole if BV is present | 125 mg IM 400 mg po | Cefpodoxime 400 mg po or Spectinomycin 2 IM or Azithromycin 2 g po in a single dose |

### PELVIC INFLAMMATORY DISEASE

| Parenteral | Either Cefotetan or Cefoxitin plus Doxycycline or Clindamycin plus Gentamicin IM/Oraj | 2 g IV q 12 hrs 2 g IV q 6 hrs 100 mg po or IV q 12 hrs 900 mg IV q 8 hrs 2 mg/kg IV or IM followed by 1.5 mg/kg IV or IM q 8 hrs | Either Ceftriaxone or Cefoxitin plus Doxycycline or Clindamycin plus Gentamicin |
| Oral | Either Ceftriaxone or Cefoxitin plus Doxycycline or Clindamycin plus Gentamicin | 250 mg IM 2 g IM, 1 g po 100 mg po bid x 14 d 500 mg po bid x 14 d |

### CERVICITIS

| Azithromycin or Doxycycline | 1 g po 100 mg po bid x 7 d 500 mg po bid x 7 d | Erythromycin base 500 mg po qid x 7 d or Erythromycin ethylsuccinate 800 mg po qid x 7 d or Levofloxacin 300 mg po bid x 7 d or Levofloxacin 500 mg po qid x 7 days |

### NONGONOCOCAL URETHRITIS

| Azithromycin or Doxycycline | 1 g po 100 mg po bid x 7 d | Erythromycin ethylsuccinate 800 mg po qid x 7 d or Levofloxacin 300 mg po bid x 7 d or Levofloxacin 500 mg po qid x 7 days |

### EPIDIDYMYSITIS

| Likely due to Gonorrhea or Chlamydia | Ceftriaxone plus Doxycycline or Levofloxacin 1 or | 250 mg IM 100 mg po bid x 10 d 300 mg po bid x 10 d 500 mg po qd x 10 d |

### TRICHOMONIASIS

| Non-pregnant Women | Metronidazole or Tinidazole 1 | 2 g po 2 g po | Metronidazole 500 mg po bid x 7 d |
| Pregnant Women | Metronidazole | 2 g po | Metronidazole 500 mg po bid x 7 d |

### BACTERIAL VAGINOSIS

| Adults/Adolescents | Metronidazole or Metronidazole gel or Clindamycin cream 16 | 500 mg po bid x 7 d 0.75%, one full applicator (5g) intravaginally qd x 5 d 2%, one full applicator (5g) intravaginally qhs x 7 d | Clindamycin 300 mg po bid x 7 d or Clindamycin ovals 100 mg intravaginally qhs x 3 d |
| Pregnant Women | Metronidazole or Metronidazole or Clindamycin | 500 mg po bid x 7 d 250 mg po tid x 7 d 300 mg po bid x 7 d |

---

1. Annual screening for women age 25 years or younger. Nucleic acid amplification tests (NAATs) are recommended. All patients should be retested 3 months after treatment for chlamydia or gonorrhea infections.
2. Contraindicated for pregnant and nursing women.
3. Every effort to use a recommended regimen, specifically ceftriaxone, should be made. Test-of-cure follow-up (preferably by NAAT) 3-4 weeks after completion of therapy is recommended in pregnancy.
4. For patients with cephalosporin allergy, anaphylaxis-type (H1-mediated) penicillin allergy or other contraindication: CDC recommends considering desensitization. However, in the vast majority of cases, this may be not feasible. Judicious use of azithromycin is a practical option if spectinomycin is not available or not indicated.
5. Cefixime has been unavailable in the U.S. since November 2002, but may become available again in the future. An oral suspension formulation is available.
6. Spectinomycin has not been manufactured since January 2006, and future availability is uncertain.
7. Cefixime tablets have not been available in the U.S. since November 2002, but may become available again in the future. An oral suspension formulation is available.
8. Every effort to use a recommended regimen, specifically ceftriaxone, should be made. Test-of-cure follow-up (preferably by NAAT) 3-4 weeks after completion of therapy is recommended in pregnancy.
9. For patients with cephalosporin allergy, anaphylaxis-type (H1-mediated) penicillin allergy or other contraindication: CDC recommends considering desensitization. However, in the vast majority of cases, this may be not feasible. Judicious use of azithromycin is a practical option if spectinomycin is not available or not indicated.
10. Cefixime has been unavailable in the U.S. since November 2002, but may become available again in the future. An oral suspension formulation is available.
11. Spectinomycin has not been manufactured since January 2006, and future availability is uncertain.
12. Use only if medical contraindications to a cephalosporin, and when spectinomycin is not available or not indicated. Test-of-cure is prudent because efficacy data are limited and because of mounting concern about emerging resistance.
13. Testing for gonorrhea and chlamydia is recommended because a specific diagnosis may improve compliance and partner management, and because these infections are reportable by California state law.
14. Evaluate for bacterial vaginosis. If present or cannot be ruled out, also use metronidazole.
15. Discontinue 24 hours after patient improves clinically and continue with oral therapy for a total of 14 days.
16. Fluoroquinolones may be used for PID in California if the risk of gonorrhea is low, a NAAT test for gonorrhea is performed, and follow-up of the patient is considered likely. If gonorrhea is documented, a test using bacterial culture should be performed and the patient should be re-treated with the recommended ceftriaxone and doxycycline regimen.
17. If local prevalence of gonorrhea is greater than 5%, consider azithromycin 1 g po in a single dose.
18. If gonorrhea is documented, a test using a medication regimen that does not include a fluoroquinolone, or obtain test-of-cure to ensure patient does not have resistant gonorrhea infection.
19. For suspected drug-resistant trichomoniasis, rule out reinfection; see 2006 CDC Guidelines, Trichomoniasis Follow-up p. 53, for other treatment options, and evaluate for metronidazole-resistant T. vaginalis. For laboratory and clinical consultations, contact CDC at 770-488-4115: http://www.cdc.gov/std.
20. Safety in pregnancy has not been established. Pregnancy category C.
21. Might weaken latex condoms and diaphragms because oil-based.

Developed by the California STD/HIV Prevention Training Center Revised November 2007
DISEASE | RECOMMENDED REGIMENS | DOSE/ROUTE | ALTERNATIVE REGIMENS: To be used if medical contraindication to recommended regimen
--- | --- | --- | ---
CHANCROID | Azithromycin or Ceftriaxone or Ciprofloxacin or Erythromycin base | 1 g po 250 mg IM 500 mg po bid x 3 d 500 mg po tid x 7 d | • Erythromycin base 500 mg po qid x 21 d or Azithromycin 1 g po q week x 3 weeks
LYMPHOGRAVLUMA VENEREUM | Doxycycline* | 100 mg po bid x 21 d |• Intravenous interferon or Laser surgery
ANOGONAL WARTS | | | 17
External genital Perianal Warts Patient Applied Intraepithelial 5% cream or Podofilox 0.5% solution or gel Topically qhs 3 x wk up to 16 wk or Topically bid x 3 d followed by 4 d no tx for up to 4 cycles
Provider Administered Cryotherapy or Podophyllin resin 10%-25% in tincture of benzoin or Trichloroacetic acid (TCA) 90%-90% or Dichloroacetic acid (BICA) 90%-90% or Surgical removal Apply once q 1-2 wks Apply once q 1-2 wks Apply once q 1-2 wks
Mucosal Genital Warts* | Cryotherapy or TCA or BICA 90%-90% or Podophyllin resin 10%-25% in tincture of benzoin or Surgical removal Vaginal, urethral meatus, and anal Vaginal and anal Urethral meatus only Anal warts only
ANOGONAL HERPES | | | 19
First Clinical Episode of Herpes | Acyclovir or Famiciclovir or Valacyclovir | 400 mg po tid x 7-10 d 200 mg po 5/day x 7-10 d 250 mg po tid x 7-10 d |• None
Established Infection Suppressive Therapy* | Acyclovir or Famiciclovir or Valacyclovir | 400 mg po bid 500 mg po qd 1 g po qd |• None
Episodic Therapy for Recurrent Episodes | Acyclovir or Famiciclovir or Valacyclovir | 400 mg po tid x 5 d 800 mg po bid x 5 d 600 mg po tid x 5 d 125 mg po bid x 5 d 1000 mg po bid x 1 d |• None
HIV Co-Infected* | Acyclovir or Famiciclovir or Valacyclovir | 400-800 mg po bid or tid 500 mg po bid 500 mg po bid |• None
Episodic Therapy for Recurrent Episodes | Acyclovir or Famiciclovir or Valacyclovir | 400 mg po tid x 5-10 d 500 mg po bid x 5-10 d 1 g po bid x 5-10 d |• None
SYPHYLIS* | | | 30
Primary, Secondary, and Early Latent | Benzathine penicillin G | 2.4 million units IM |• Doxycycline 100 mg po bid x 14 d or Tetracycline 500 mg po qid x 14 d or Ceftriaxone 1 g IM or IV qd x 10-14 d
Late Latent and Latent of Unknown duration | Benzathine penicillin G | 7.2 million units, administered as 3 doses of 2.4 million units IM each, at 1-week intervals |• Doxycycline 100 mg po bid x 28 d or Tetracycline 500 mg po qd x 28 d
Neurosyphilis* | Aqueous crystalline penicillin G | 18-24 million units daily, administered as 3-4 million units IV q 4 hrs x 10-14 d |• Procaine penicillin G, 2.4 million units IM qd x 10-14 d plus Probencid 500 mg po qid x 10-14 d or Ceftriaxone 2 g IM or IV qd x 10-14 d
Pregnant Women* | Benzathine penicillin G | 2.4 million units IM |• None
Late Latent and Latent of Unknown duration | Benzathine penicillin G | 7.2 million units, administered as 3 doses of 2.4 million units IM each, at 1-week intervals |• None
Neurosyphilis* | Aqueous crystalline penicillin G | 18-24 million units daily, administered as 3-4 million units IV q 4 hrs x 10-14 d |• Procaine penicillin G, 2.4 million units IM qd x 10-14 d plus Probencid 500 mg po qid x 10-14 d
HIV Co-Infected | Benzathine penicillin G | 2.4 million units IM |• Doxycycline 100 mg po bid x 14 d or Tetracycline 500 mg po qid x 14 d
Late Latent, and Late of Unknown duration with normal CSF Exam | Benzathine penicillin G | 7.2 million units, administered as 3 doses of 2.4 million units IM each, at 1-week intervals |• Doxycycline 100 mg po bid x 28 d
Neurosyphilis* | Aqueous crystalline penicillin G | 18-24 million units daily, administered as 3-4 million units IV q 4 hrs x 10-14 d |• Procaine penicillin G, 2.4 million units IM qd x 10-14 d plus Probencid 500 mg po qid x 10-14 d or Ceftriaxone 2 g IM or IV qd x 10-14 d

17. Contraindicated in pregnancy. 18. Cervical warts should be managed by a specialist. 19. Counseling about natural history, asymptomatic shedding, and sexual transmission is an essential component of herpes management. 20. The goal of suppressive therapy is to reduce recurrent symptomatic episodes and/or to reduce sexual transmission. 21. If HSV lesions persist or recur while receiving antiviral treatment, antiviral resistance should be suspected. A viral isolate should be obtained for sensitivity testing, and consultation with an infectious disease expert is recommended. 22. Benzathine penicillin G (generic name) is the recommended treatment for syphilis not involving the central nervous system and is available in only one long-acting formulation, Bicillin® L-A (the trade name) which contains only benzathine penicillin G. Other combination products, such as Bicillin® C-R, contain both long- and short-acting penicillins and are not effective for treating syphilis. 23. Alternates should only be used for penicillin-allergic patients because efficacy of these therapies has not been established. Compliance with some of these regimens is difficult, and close follow-up is essential. If compliance or follow-up cannot be ensured, the patient should be desensitized and treated with benzathine penicillin. 24. Some specialists recommend 2.4 million units of benzathine penicillin G week for up to 3 weeks after completion of neurosyphilis treatment. 25. Patients allergic to penicillin should be treated with penicillin after desensitization.